{"product_id":"drug-synthesis-book-set-isbn-9781119185659","title":"Drug Synthesis Book Set","description":"This set presents the authoritative and acclaimed Drug Synthesis books edited by Jie Jack Li and Douglas Johnson: \u003ci\u003eContemporary Drug Synthesis\u003c\/i\u003e, \u003ci\u003eThe Art of Drug Synthesis\u003c\/i\u003e, \u003ci\u003eModern Drug Synthesis, \u003c\/i\u003eand\u003ci\u003e Innovative Drug Synthesis\u003c\/i\u003e. This book set will be enormously useful to pharmaceutical industry labs, research scientists in lead optimization and process development, and graduate students and courses in organic chemistry, synthetic organic chemistry, heterocyclic chemistry, medicinal chemistry, and drug synthesis courses. \u003cb\u003e\u003ci\u003eContemporary Drug Synthesis\u003c\/i\u003e\u003c\/b\u003e \u003cp\u003ePreface v\u003c\/p\u003e \u003cp\u003eTrade Names and Their Corresponding USANs xi\u003c\/p\u003e \u003cp\u003eAcronyms and Abbreviations xiii\u003c\/p\u003e \u003cp\u003eChapter 1. Antithrombotics: Ticlopidine (Ticlid) and Clopidogrel (Plavix) 1\u003c\/p\u003e \u003cp\u003eChapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex) and Rofecoxib (Vioxx) 11\u003c\/p\u003e \u003cp\u003eChapter 3. H\u003csup\u003e+\u003c\/sup\u003e\/K\u003csup\u003e+\u003c\/sup\u003e -ATPase Inhibitors: Esomeprazole (Nexium) 21\u003c\/p\u003e \u003cp\u003eChapter 4. Protein-tyrosine Kinase Inhibitors: Imatnib (Gleevec) and Gefitinib (Iressa) 29\u003c\/p\u003e \u003cp\u003eChapter 5. Non-sedating Antihistamines 39\u003c\/p\u003e \u003cp\u003eChapter 6. Cosmeceuticals: Istretinoin (Accutane), Tazarotene (Tazorac), Minoxidil (Rogaine), and Finasteride (Propecia) 55\u003c\/p\u003e \u003cp\u003eChapter 7. Antibacterials: Ciprofloxacin (Cipro) and Linezolid (Zyvox) 75\u003c\/p\u003e \u003cp\u003eChapter 8. Atypical Antupsychotics 89\u003c\/p\u003e \u003cp\u003eChapter 9. Atovastatin Calcium (Lipitor) 113\u003c\/p\u003e \u003cp\u003eChapter 10. Antidepressants 125\u003c\/p\u003e \u003cp\u003eChapter 11. Anti-obesity: Orlistat (Xenical) 149\u003c\/p\u003e \u003cp\u003eChapter 12. Triptans for Migrane 161\u003c\/p\u003e \u003cp\u003eChapter 13. PDE 5 Inhibitors for Erectile Dysfunction: Sildenafil (Viagra), Vardenafil (Levitra), and Tadalafil (Cialis) 189\u003c\/p\u003e \u003cp\u003eChapter 14. Antiasthmatics 201\u003c\/p\u003e \u003cp\u003eIndex 214\u003c\/p\u003e \u003cp\u003e\u003ci\u003e\u003cb\u003eThe Art of Drug Synthesis\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY 1\u003cbr\u003e\u003ci\u003eJohn A. Lowe, III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 PROCESS RESEARCH: HOW MUCH? HOW SOON? 11\u003cbr\u003e\u003ci\u003eNeal G. Anderson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) 31\u003cbr\u003e\u003ci\u003eJie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) 39\u003cbr\u003e\u003ci\u003eChris Limberakis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) 71\u003cbr\u003e\u003ci\u003eAndrew S. Bell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS 83\u003cbr\u003e\u003ci\u003eArthur Harms\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) 95\u003cbr\u003e\u003ci\u003eDouglas S. Johnson and Jie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES 117\u003cbr\u003e\u003ci\u003eJin Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION 129\u003cbr\u003e\u003ci\u003eLarry Yet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 LEADING ACE INHIBITORS FOR HYPERTENSION 143\u003cbr\u003e\u003ci\u003eVictor J. Cee and Edward J. Olhava\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION 159\u003cbr\u003e\u003ci\u003eDaniel P. Christen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS 169\u003cbr\u003e\u003ci\u003eJeffrey A. Pfefferkorn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) 183\u003cbr\u003e\u003ci\u003eStuart B. Rosenblum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION 199\u003cbr\u003e\u003ci\u003eMarta Pineiro-Nunez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON 215\u003cbr\u003e\u003ci\u003ePeter R. Guzzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Alpha2Delta LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) 225\u003cbr\u003e\u003ci\u003ePo-Wai Yuen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) 241\u003cbr\u003e\u003ci\u003eDavid L. Gray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReferences 257\u003c\/p\u003e \u003cp\u003eIndex 261\u003c\/p\u003e \u003cp\u003e\u003ci\u003e\u003cb\u003eModern Drug Synthesis\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e Preface xi \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eI. Infectious Diseases 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor 3\u003cbr\u003e\u003ci\u003eJulianne A. Hunt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 2. Maraviroc (Selzentry), The First-in-class CCR5 Antagonist for the Treatment of HIV 17\u003cbr\u003e\u003ci\u003eDavid Price\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 3. Darunavir (Prezista), A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV 29\u003cbr\u003e\u003ci\u003eArun K. Ghosh and Cuthbert D. Martyr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eII. Cancer 45\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 4. Decitabine (Dacogen), A DNA Methyltransferase Inhibitor for Cancer 47\u003cbr\u003e\u003ci\u003eJennifer A. Van Camp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 5. Capecitabine (Xeloda), An Oral Chemotherapy Agent 57\u003cbr\u003e\u003ci\u003eR. Jason Herr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 6. Sorafenib (Nexavar), A Multi-kinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma 73\u003cbr\u003e\u003ci\u003eShuanghua Hu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor 87\u003cbr\u003e\u003ci\u003eMartin Pettersson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor 99\u003cbr\u003e\u003ci\u003eBenjamin S. Greener and David S. Millan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer 111\u003cbr\u003e\u003ci\u003eJi Zhang and Jie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIII. Cardiovascular and Metabolic Diseases 123\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes 125\u003cbr\u003e\u003ci\u003eScott D. Edmondson, Feng Xu, and Joseph D. Armstrong III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 11. Aliskiren (Tekturna), The First-in-class Renin Inhibitor for Hypertension 141\u003cbr\u003e\u003ci\u003eVictor J. Cee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 12. Vernakalant (Kynapid), An Investigational Drug for the Treatment of Atrial Fibrillation 159\u003cbr\u003e\u003ci\u003eDavid L. Gray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 13. Conivaptan (Vaprisol), Vasopressin V1a and V2 Antagonist for Hyponatremia 175\u003cbr\u003e\u003ci\u003eBrian A. Lanman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 14. Rivaroxaban (Xarelto), A Factor Xa Inhibitor for the Treatment of Thrombotic Events 191\u003cbr\u003e\u003ci\u003eJi Zhang and Jason Crawford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 15. Endothelin Antagonists for the Treatment of Pulmonary Arterial Hypertension 207\u003cbr\u003e\u003ci\u003eDavid Edmonds\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIV. Central Nervous System Diseases 225\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 16. Varenicline (Chantix), An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation 227\u003cbr\u003e\u003ci\u003eJotham W. Coe, Frank R. Busch and Robert A. Singer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 17. Donepezil, Rivastigmine, Galantamine: Cholinesterase Inhibitors for Alzheimer's Disease 249\u003cbr\u003e\u003ci\u003eSubas Sakya and Kapil Karki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 18. Aprepitant (Emend), A NK1 Receptor Antagonist for the Treatment of Post-chemotherapy Emesis 275\u003cbr\u003e\u003ci\u003eJohn A. Lowe, III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 19. Armodafinil (Nuvigil), A Psychostimulant for the Treatment of Narcolepsy 291\u003cbr\u003e\u003ci\u003eJi Zhang and Jason Crawford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eV. Miscellaneous 307\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 20. Raloxifene (Evista), A Selective Estrogen Receptor Modulator (SERM) 309\u003cbr\u003e\u003ci\u003eMarta Piñeiro-Núñez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 21. Latanoprost (Xalatan), A Prostanoid FP Agonist for Glaucoma 329\u003cbr\u003e\u003ci\u003eSajiv K. Nair and Kevin E. Henegar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 339\u003c\/p\u003e \u003cp\u003e\u003ci\u003e\u003cb\u003eInnovative Drug Synthesis\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I. INFECTIOUS DISEASES 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1. Entecavir (Baraclude): A Carbocyclic Nucleoside for the Treatment of Chronic Hepatitis B 3\u003c\/p\u003e \u003cp\u003eChapter 2. Telaprevir (Incivek) and Boceprevir (Victrelis): NS3\/4A Inhibitors for Treatment for Hepatitis C Virus (HCV) 15\u003c\/p\u003e \u003cp\u003eChapter 3. Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor 43\u003c\/p\u003e \u003cp\u003eChapter 4. Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor 61\u003c\/p\u003e \u003cp\u003eChapter 5. Bedaquiline (Sirturo): A Diarylquinoline that Blocks Tuberculosis ATP Synthase for the Treatment of Multi-Drug Resistant Tuberculosis 81\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II. CANCER 99\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 6. Enzalutamide (Xtandi): An Androgen Receptor Antagonist for Late-Stage Prostate Cancer 101\u003c\/p\u003e \u003cp\u003eChapter 7. Crizotinib (Xalkori): The First-in-Class ALK\/ROS Inhibitor for Non-small Cell Lung Cancer 119\u003c\/p\u003e \u003cp\u003eChapter 8. Ibrutinib (Imbruvica): The First-in-Class Btk Inhibitor for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia 157\u003c\/p\u003e \u003cp\u003eChapter 9. Palbociclib (Ibrance): The First-in-Class CDK4\/6 Inhibitor for Breast Cancer 167\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III. CARDIOVASCULAR DISEASES 197\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 10. Ticagrelor (Brilinta) and Dabigatran Etexilate (Pradaxa): P2Y12 Platelet Inhibitors as Anti-coagulants 199\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV. CNS DRUGS 223\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 11. Suvorexant (BELSOMRA): The First-in-Class Orexin Antagonist for Insomnia 225\u003c\/p\u003e \u003cp\u003eChapter 12. Lorcaserin (Belviq): Serotonin 2C Receptor Agonist for the Treatment of Obesity 243\u003c\/p\u003e \u003cp\u003eChapter 13. Fingolimod (Gilenya): The First Oral Treatment for Multiple Sclerosis 255\u003c\/p\u003e \u003cp\u003eChapter 14. Perampanel (Fycompa): AMPA Receptor Antagonist for the Treatment of Seizure 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART V. ANTI-INFLAMMATORY DRUGS 283\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 15. Tofacitinib (Xeljanz): The First-in-Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis 285\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART VI. MISCELLANEOUS DRUGS 303\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 16. Ivacaftor (Kalydeco): A CFTR Potentiator for the Treatment of Cystic Fibrosis 305\u003c\/p\u003e \u003cp\u003eChapter 17. Febuxostat (Uloric): A Xanthine Oxidase Inhibitor for the Treatment of Gout 317\u003c\/p\u003e \u003cp\u003eIndex 331\u003c\/p\u003e \u003cp\u003e\u003cb\u003eJie Jack Li \u003c\/b\u003eis an Associate Professor of chemistry at the University of San Francisco. Previously, he was a chemist at Bristol-Myers Squibb Company. He has authored or edited several books published by Wiley, including \u003ci\u003eDrug Discovery: Practices, Processes, and Perspectives\u003c\/i\u003e, \u003ci\u003eHeterocyclic Chemistry in Drug Discovery\u003c\/i\u003e, \u003ci\u003eName Reactions in Heterocyclic Chemistry\u003c\/i\u003e, \u003ci\u003eName Reactions for Functional Group Transformations\u003c\/i\u003e, \u003ci\u003eContemporary Drug Synthesis\u003c\/i\u003e, \u003ci\u003eThe Art of Drug Synthesis\u003c\/i\u003e, and \u003ci\u003eModern Drug Synthesis\u003c\/i\u003e.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eDouglas Johnson \u003c\/b\u003eis an Associate Research Fellow and head of Chemical Biology in the Neuroscience Medicinal Chemistry group at Pfizer Worldwide Research and Development. He is a co-author on more than 70 publications and patents and is a co-author of the book \u003ci\u003eContemporary Drug Synthesis\u003c\/i\u003e and is an editor of \u003ci\u003eThe Art of Drug Synthesis\u003c\/i\u003e, and \u003ci\u003eModern Drug Synthesis\u003c\/i\u003e (all published by Wiley).\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989088551141,"sku":"NP9781119185659","price":476.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119185659.jpg?v=1761782747","url":"https:\/\/k12savings.com\/products\/drug-synthesis-book-set-isbn-9781119185659","provider":"K12savings","version":"1.0","type":"link"}